Ikonomou spoke with ScienceBoard.net about the ethical and regulatory issues around the rapid growth of the global CGT industry, as the ISCT 2022 annual meeting kicked off in San Francisco this week.

The ISCT Committee on the Ethics of Cell and Gene Therapy is composed of international experts charged with examining unproven and unethical CGT interventions and promoting safe and effective practices around the world. Ikonomou describes it as a "borderless" direct-to-consumer problem in many countries.

For example, in the U.S. during the COVID-19 pandemic, Ikonomou said direct-to-consumer businesses have made unsubstantiated and inaccurate claims about purported "stem cell" products for the coronavirus. Researchers have called for stronger regulations to deter the sale of unproven cell-based products, and more responsible and accurate science communication.

Watch the video below to learn more.

Advances in gene therapy call for education, patient advocate says
Durhane Wong-Rieger, board chair of Rare Diseases International, spoke to ScienceBoard.net at the Cell & Gene Meeting on the Med last week in...

Investment continues in cell and gene sector, despite disruptions
Investment in the cell and gene therapy sector remains robust, despite the disruptions over the last several years due to the COVID-19 pandemic. That's...

EBRC explains new ethics in engineering research statement
The Engineering Biology Research Consortium (EBRC) has published a companion paper to its Statement of Ethics in Engineering Biology Research. The new...

Science serves society, a crucial concept for gene therapy governance
With a focus on science and society, the American Society of Gene & Cell Therapy Policy Summit commenced on September 24. The ensuing discussion revealed...